European Drug Discovery Services 2026: CRO, Medicinal Chemistry, ADMET, DMPK

Three operators dominate the European drug-discovery CRO count in the directory. Evotec (Hamburg, Germany) is the largest pan-European integrated drug-discovery CRO the directory surfaces — covering target identification, hit discovery, lead optimisation, medicinal chemistry, in-vivo pharmacology, DMPK, and early clinical development at global scope with listed commercial scale. Selvita (Kraków, Poland) is the CEE drug-discovery anchor with medicinal chemistry, biology, and DMPK services plus development-services capacity downstream. Charles River Laboratories Finland (Kuopio) provides European preclinical toxicology + early-development services as part of the global Charles River network. Together these three cover full-service discovery + preclinical needs for most European sponsor programmes. For medicinal-chemistry-heavy work, Selvita is the CEE-based directory option. For integrated end-to-end discovery, Evotec is the directory’s largest full-service European option. For preclinical toxicology + regulatory-study support, Charles River Finland is the Nordic entry to the global Charles River network.

ADMET (absorption, distribution, metabolism, excretion, toxicity) and DMPK services are a distinct European specialism the directory surfaces. Admescope (Oulu, Finland) runs a dedicated ADMET + in-vitro drug metabolism CRO service — one of the few directory operators focused exclusively on the ADMET axis. Evotec and Selvita both run DMPK as part of their full-service stacks. Around Oulu, Paras Biopharmaceuticals and Pharmatory provide chemistry + CDMO services adjacent to the ADMET layer. For sponsors running discovery-to-preclinical programmes that need deep ADMET characterisation, Admescope is the specialist option; Evotec or Selvita is the choice when ADMET is bundled into a larger discovery programme.

Switzerland hosts a specialised discovery-tools cluster that the European drug-discovery ecosystem relies on. Biognosys (Schlieren) runs mass-spectrometry-based proteomics services for target identification and pharmacodynamic biomarker workflows. InSphero (Schlieren) and SUN bioscience (Lausanne) operate 3D tissue model + organoid assay services used by sponsors running target validation and early-efficacy workflows. Epithelix (Plan-les-Ouates) runs in-vitro human airway models (MucilAir) used in respiratory + inhaled drug programmes. Myria Biosciences (Basel) adds an early-stage discovery biotech operating in the Basel cluster. For sponsors running discovery programmes that depend on proteomics readouts, 3D tissue models, or inhaled-drug screening, these are the Swiss operators the directory surfaces.

Poland is the largest CEE drug-discovery geography by directory count. Selvita (Kraków) is the CRO anchor. Ryvu Therapeutics (Kraków) runs an in-house oncology pipeline using discovery infrastructure historically shared with Selvita. Molecure (Warsaw) operates small-molecule drug discovery with mRNA-target focus at clinical stage. Pikralida (Poznań) develops therapeutics at early-clinical stage. The Jagiellonian Centre of Innovation in Kraków provides life-science park infrastructure around the Jagiellonian University Medical College. For sponsors looking at CEE drug-discovery partnerships — Selvita for CRO services, Ryvu for in-house pipeline collaboration, Molecure for mRNA-target partnerships — Poland holds the highest CEE operator count the directory surfaces.

The European drug-discovery layer is anchored to an academic + translational-research infrastructure. AstraZeneca Gothenburg is the largest directory-listed Swedish pharma R&D site, with in-house discovery covering cardiovascular, renal, metabolic, oncology, respiratory, immunology, and neuroscience. The BioInnovation Institute (Copenhagen) runs as a translational-research incubator with early-stage biotech programmes. The Latvian Institute of Organic Synthesis (Riga) runs academic + applied chemistry research adjacent to the Polish Kraków discovery hub. Klaipeda University Health Research and Innovation Science Centre adds Lithuanian translational infrastructure. Germany’s broader research layer (EMBL Heidelberg, DKFZ, Max Delbrück Center Berlin) is covered in the German Biotech Landscape 2026 brief. For sponsors partnering on translational or early-discovery programmes, these academic and semi-academic operators are the discovery-adjacent reference points.

Drug discovery workflows depend on a tools + consumables + analytical-instruments layer the directory surfaces. Biotage (Uppsala, Sweden) runs separation, purification, and scavenger/reagent tools used across medicinal chemistry workflows. Evosep (Odense, Denmark) runs proteomics sample-preparation instruments (the Evosep One system). Biognosys (Schlieren, Switzerland) runs mass-spectrometry proteomics services. Combined with the pan-European reagent + consumables distribution through Thermo Fisher Supply (Vilnius, Warsaw) + Avantor/VWR (Darmstadt, Gdańsk), these operators form the discovery-adjacent supply layer — see the European Pharma Cold Chain & GDP Logistics 2026 brief for the distribution context.

Match the decision to the work. Full-service integrated discovery (target identification to early development): Evotec. CEE-based medicinal chemistry + biology + DMPK: Selvita. Preclinical toxicology + regulatory-study support: Charles River Laboratories Finland. Obesity / cardiometabolic specialist CRO: Gubra (Hørsholm). Dedicated ADMET + drug metabolism: Admescope (Oulu). Proteomics readouts + target ID: Biognosys. 3D tissue model + organoid screening: InSphero or SUN bioscience. In-vitro airway + inhaled drug: Epithelix. Translational + academic partnership: BioInnovation Institute Copenhagen or the Institute of Organic Synthesis (Latvia). Polish mRNA-target collaboration: Molecure. Polish in-house oncology-pipeline partnership: Ryvu Therapeutics. Separation + purification tools: Biotage. Proteomics sample-prep instruments: Evosep. The How to Pick a European Biotech Partner 2026 brief covers cross-modality partner selection.